Schambelan M, Blake S, Sraer J, Bens M, Nivez M P, Wahbe F
J Clin Invest. 1985 Feb;75(2):404-12. doi: 10.1172/JCI111714.
Abnormalities in glomerular function have been observed frequently in the early stages of both clinical and experimental diabetes mellitus. Because prostaglandins (PGs) are present in the glomerulus and have profound effects on glomerular hemodynamics, and because abnormalities of PG metabolism have been noted in other tissues from diabetics, we studied PG biosynthesis in glomeruli obtained from rats in the early stages of experimental diabetes mellitus. Streptozotocin, 60 mg/kg, was administered intravenously to male Sprague-Dawley rats. Control rats received an equal volume of the vehicle. Glomeruli were isolated 9-23 d later. Production of eicosanoids was determined by two methods: by direct radioimmunoassay after incubation of glomeruli under basal conditions and in the presence of arachidonic acid (C20:4), 30 microM, and by radiometric high-performance liquid chromatography (HPLC) after incubation of glomeruli with [14C]C20:4. When assessed by radioimmunoassay, mean basal production of both prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2 alpha) was twofold greater in the diabetic animals whereas production of thromboxane B2 (TXB2) was not significantly greater than control. In response to C20:4, both PGE2 and PGF2 alpha were also greater in the diabetic animals, but these differences were not statistically significant. The increased rate of basal PG production did not appear to be related directly to the severity of the diabetic state as reflected by the degree of hyperglycemia at the time of sacrifice. In fact, the rates of glomerular PG production in the individual diabetic animals correlated inversely with the plasma glucose concentration. The increased rate of PG synthesis did not appear to be due to a nonspecific effect of streptozotocin inasmuch as glomerular PG production was not increased significantly in streptozotocin-treated rats which were made euglycemic by insulin therapy. Furthermore, addition of streptozotocin, 1-10 mM, to the incubation media had no effect on PGE2 production by normal glomeruli. PGE2 production by normal glomeruli was also not influenced by varying the glucose concentration in the incubation media over a range of 1-40 mM. When metabolism of [14C]C20:4 was evaluated by high-performance liquid chromatography conversion to labeled PGE2, PGF2 alpha, TXB2, and hydroxyheptadecatrienoic acid by diabetic glomeruli was two- to threefold greater compared with that in control glomeruli, whereas no significant difference in conversion to 12- and 15-hydroxyeicosatetraenoic acid occurred. These findings indicate that glomerular cyclooxygenase but not lipoxygenase activity was increased in the diabetic animals. A concomitant increase in glomerular phospholipase activity may also have been present to account for the more pronounced differences in PG production noted in the absence of exogenous unlabeled C20:4. These abnormalities in PG biosynthesis by diabetic glomeruli may contribute to the altered glomerular hemodynamics in this pathophysiologic setting.
在临床和实验性糖尿病的早期阶段,经常观察到肾小球功能异常。由于前列腺素(PGs)存在于肾小球中,对肾小球血流动力学有深远影响,并且在糖尿病患者的其他组织中已注意到PG代谢异常,因此我们研究了实验性糖尿病早期大鼠肾小球中的PG生物合成。将60mg/kg链脲佐菌素静脉注射给雄性Sprague-Dawley大鼠。对照大鼠接受等量的赋形剂。9-23天后分离肾小球。通过两种方法测定类花生酸的产生:在基础条件下和存在30μM花生四烯酸(C20:4)的情况下孵育肾小球后,通过直接放射免疫测定法;以及在肾小球与[14C]C20:4孵育后,通过放射性高效液相色谱(HPLC)测定。通过放射免疫测定评估时,糖尿病动物中前列腺素E2(PGE2)和前列腺素F2α(PGF2α)的平均基础产生量是对照组的两倍,而血栓素B2(TXB2)的产生量并不显著高于对照组。对C20:4的反应,糖尿病动物中PGE2和PGF2α也更高,但这些差异无统计学意义。基础PG产生率的增加似乎与牺牲时高血糖程度所反映的糖尿病状态的严重程度没有直接关系。事实上,个体糖尿病动物中肾小球PG产生率与血浆葡萄糖浓度呈负相关。PG合成率的增加似乎不是由于链脲佐菌素的非特异性作用,因为通过胰岛素治疗使血糖正常的链脲佐菌素处理大鼠中肾小球PG产生并未显著增加。此外,向孵育培养基中添加1-10mM链脲佐菌素对正常肾小球的PGE2产生没有影响。在1-40mM范围内改变孵育培养基中的葡萄糖浓度也不影响正常肾小球的PGE2产生。当通过高效液相色谱评估[14C]C20:4的代谢时,糖尿病肾小球将其转化为标记的PGE2、PGF2α、TXB2和羟基十七碳三烯酸的量比对照肾小球高两到三倍,而转化为12-和15-羟基二十碳四烯酸则没有显著差异。这些发现表明,糖尿病动物中肾小球环氧化酶活性增加,而脂氧化酶活性未增加。可能还存在肾小球磷脂酶活性的伴随增加,以解释在没有外源性未标记C20:4的情况下PG产生中更明显的差异。糖尿病肾小球中PG生物合成的这些异常可能导致这种病理生理环境中肾小球血流动力学的改变。